Yonhap Infomax NewsOct 15
Celltrion has received regulatory approval in New Zealand for Stekeyma, its biosimilar to Stelara, expanding access to autoimmune disease treatments in a $21.66 billion global market.
#YonhapInfomax #Celltrion #Stekeyma #Biosimilar #Ustekinumab #NewZealandApproval #Economics #FinancialMarkets #Banking #Securities #Bonds #StockMarket
https://en.infomaxai.com/news/articleView.html?idxno=85542
Celltrion Secures Regulatory Approval for Autoimmune Disease Biosimilar 'Stekeyma' in New Zealand

Celltrion has received regulatory approval in New Zealand for Stekeyma, its biosimilar to Stelara, expanding access to autoimmune disease treatments in a $21.66 billion global market.

Yonhap Infomax